Discovery of a novel activator of KCNQ1-KCNE1 K± channel complexes

PLoS ONE

Volumn 4, Issue 1, 2009, Pages

  Mruk, Karen ^a   Kobertz, William R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENEBORONIC ACID; BORONIC ACID DERIVATIVE; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNQ; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; POTASSIUM CHANNEL KCNQ4; SHAKER POTASSIUM CHANNEL; COMPLEMENTARY DNA; KCNE1 PROTEIN, HUMAN; PEPTIDE; POTASSIUM CHANNEL BLOCKING AGENT; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL CELL; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; ION CONDUCTANCE; ION CURRENT; NONHUMAN; OOCYTE; PROTEIN EXPRESSION; XENOPUS; ANIMAL; BIOLOGICAL MODEL; CELL MEMBRANE POTENTIAL; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY;

ANIMALS; BORONIC ACIDS; DNA, COMPLEMENTARY; ELECTROPHYSIOLOGY; GENE EXPRESSION REGULATION; ION CHANNEL GATING; KCNQ1 POTASSIUM CHANNEL; MEMBRANE POTENTIALS; MODELS, BIOLOGICAL; OOCYTES; PEPTIDES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; XENOPUS;

EID: 58849099205     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004236     Document Type: Article

References (44)

1. Robbins J (2001) KCNQ potassium channels: physiology, pathophysiology, and pharmacology. Pharmacol Ther 90: 1-19.
2. Cooper EC, Jan LY (2003) M-channels: neurological diseases, neuromodulation, and drug development. Arch Neurol 60: 496-500.
3. Jentsch TJ (2000) Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 1: 21-30.
4. Kubisch C, Schroeder BC, Friedrich T, Lutjohann B, El-Amraoui A, et al. (1999) KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell 96: 437-446.
5. Kharkovets T, Hardelin JP, Safieddine S, Schweizer M, El-Amraoui A, et al. (2000) KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci U S A 97: 4333-4338.
6. Jespersen T, Grunnet M, Olesen SP (2005) The KCNQ1 potassium channel: from gene to physiological function. Physiology (Bethesda) 20: 408-416.
7. McCrossan ZA, Abbott GW (2004) The MinK-related peptides. Neuropharmacology 47: 787-821.
8. Ks potassium channel. Nature 384: 80-83.
9. Ks cardiac potassium current. Nature 384: 78-80.
10. Neyroud N, Tesson F, Denjoy I, Leibovici M, Donger C, et al. (1997) A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet 15: 186-189.
11. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, et al. (2000) Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 102: 1178-1185.
12. Roepke TK, Anantharam A, Kirchhoff P, Busque SM, Young JB, et al. (2006) The KCNE2 potassium channel ancillary subunit is essential for gastric acid secretion. J Biol Chem 281: 23740-23747.
13. Schroeder BC, Waldegger S, Fehr S, Bleich M, Warth R, et al. (2000) A constitutively open potassium channel formed by KCNQ1 and KCNE3. Nature 403: 196-199.
14. + channels. J Gen Physiol 131: 59-68.
15. Nakajo K, Kubo Y (2007) KCNE1 and KCNE3 Stabilize and/or Slow Voltage Sensing S4 Segment of KCNQ1 Channel. J Gen Physiol 130: 269-281.
16. Panaghie G, Abbott GW (2007) The role of S4 charges in voltage-dependent and voltage-independent KCNQ1 potassium channel complexes. J Gen Physiol 129: 121-133.
17. MacKinnon R, Yellen G (1990) Mutations affecting TEA blockade and ion permeation in voltage-activated K+ channels. Science 250: 276-279.
18. Yellen G, Jurman ME, Abramson T, MacKinnon R (1991) Mutations affecting internal TEA blockade identify the probable pore-forming region of a K+ channel. Science 251: 939-942.
19. Choi KL, Aldrich RW, Yellen G (1991) Tetraethylammonium blockade distinguishes two inactivation mechanisms in voltage-activated K+ channels. Proc Natl Acad Sci U S A 88: 5092-5095.
20. Baukrowitz T, Yellen G (1996) Use-dependent blockers and exit rate of the last ion from the multi-ion pore of a K+ channel. Science 271: 653-656.
21. Xiong Q, Gao Z, Wang W, Li M (2008) Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds. Trends Pharmacol Sci 29: 99-107.
22. Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, et al. (2005) International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 57: 473-508.
23. Lerche C, Seebohm G, Wagner CI, Scherer CR, Dehmelt L, et al. (2000) Molecular impact of MinK on the enantiospecific block of I(Ks) by chromanols. Br J Pharmacol 131: 1503-1506.
24. + Channels. J Gen Physiol 124: 759-771.
25. Seebohm G, Chen J, Strutz N, Culberson C, Lerche C, et al. (2003) Molecular determinants of KCNQ1 channel block by a benzodiazepine. Mol Pharmacol 64: 70-77.
26. Busch AE, Busch GL, Ford E, Suessbrich H, Lang HJ, et al. (1997) The role of the IsK protein in the specific pharmacological properties of the IKs channel complex. Br J Pharmacol 122: 187-189.
27. Salata JJ, Jurkiewicz NK, Wang J, Evans BE, Orme HT, et al. (1998) A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents. Mol Pharmacol 54: 220-230.
28. Gao Z, Xiong Q, Sun H, Li M (2008) Desensitization of chemical activation by auxiliary subunits: Convergence of molecular determinants critical for augmenting KCNQ1 potassium channels. J Biol Chem 283: 22649-22658.
29. Abitbol I, Peretz A, Lerche C, Busch AE, Attali B (1999) Stilbenes and fenamates rescue the loss of I(KS) channel function induced by an LQT5 mutation and other IsK mutants. Embo J 18: 4137-4148.
30. Patthy L, Smith EL (1975) Reversible modification of arginine residues. Application to sequence studies by restriction of tryptic hydrolysis to lysine residues. J Biol Chem 250: 557-564.
31. Seebohm G, Sanguinetti MC, Pusch M (2003) Tight coupling of rubidium conductance and inactivation in human KCNQ1 potassium channels. J Physiol 552: 369-378.
32. Pusch M, Bertorello L, Conti F (2000) Gating and flickery block differentially affected by rubidium in homomeric KCNQ1 and heteromeric KCNQ1/KCNE1 potassium channels. Biophys J 78: 211-226.
33. Schwake M, Pusch M, Kharkovets T, Jentsch TJ (2000) Surface Expression and Single Channel Properties of KCNQ2/KCNQ3, M-type K+ Channels Involved in Epilepsy. J Biol Chem 275: 13343-13348.
34. Selyanko AA, Hadley JK, Brown DA (2001) Properties of single M-type KCNQ2/KCNQ3 potassium channels expressed in mammalian cells. J Physiol 534: 15-24.
35. Li Y, Gamper N, Shapiro MS (2004) Single-channel analysis of KCNQ K+ channels reveals the mechanism of augmentation by a cysteine-modifying reagent. J Neurosci 24: 5079-5090.
36. Li Y, Gamper N, Hilgemann DW, Shapiro MS (2005) Regulation of Kv7 (KCNQ) K+ Channel Open Probability by Phosphatidylinositol 4,5-Bisphosphate. J Neurosci 25: 9825-9835.
37. Sesti F, Goldstein SA (1998) Single-channel characteristics of wild-type IKs channels and channels formed with two minK mutants that cause long QT syndrome. J Gen Physiol 112: 651-663.
38. Yang Y, Sigworth FJ (1998) Single-channel properties of IKs potassium channels. J Gen Physiol 112: 665-678.
39. Yan J, Springsteen G, Deeter S, Wang B (2004) The relationship among pKa, pH, and binding constants in the interactions between boronic acids and diols-it is not as simple as it appears. Tetrahedron 60: 11205-11209.
40. Springsteen G, Wang B (2002) A detailed examination of boronic acid-diol complexation. Tetrahedron 58: 5291-5300.
41. Roche JP, Westenbroek R, Sorom AJ, Hille B, Mackie K, et al. (2002) Antibodies and a cysteine-modifying reagent show correspondence of M current in neurons to KCNQ2 and KCNQ3 K+ channels. Br J Pharmacol 137: 1173-1186.
42. Mitcheson JS, Chen J, Sanguinetti MC (2000) Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol 115: 229-240.
43. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 97: 12329-12333.
44. Bunn PA Jr (2004) The potential role of proteasome inhibitors in the treatment of lung cancer. Clin Cancer Res 10: 4263s-4265s.